

Subtotal: 252
Subtotal: 453
1242 Subjects
1242 Subjects
R
JNJ-3093 25 mg BID (N=153)
JNJ-3093 50 mg BID (N=150)
JNJ-3093 100 mg BID (N=152)
JNJ-3093 200 mg BID (N=153)
JNJ-3093 25 mg QD (N=34)
JNJ-3093 50 mg QD (N=150)
JNJ-3093 200 mg QD (N=149)
Open-Label Enoxaparin SC 40 mg QD (N=301)
IA #1*
IA #2**

FIG. 1



Percent Incidence
30
20
10
0
Enoxaparin
25 mg
50 mg
100 mg
200 mg
Milvexian BID
25 mg
50 mg
200 mg
Milvexian Once Daily

FIG. 2



% Incidence Rate
0
5
10
15
20
25
Enoxaparin
25mg BID
50mg BID
100mg BID
200mg BID
25mg qd
50mg qd
200mg qd
>2/3 of the length of vein segment
>1/3 but, 2/3
<1/3

FIG. 3



Average Severity Score
0
1
2
3
4
5
6
7
Enoxaparin
25 mg
50 mg
100 mg
200 mg
Milvexian BID
25 mg
50 mg
200 mg
Milvexian qd

FIG. 4



Percent Incidence
0
4
8
Enoxaparin
25 mg
50 mg
100 mg
200 mg
Milvexian BID
25 mg
50 mg
200 mg
Milvexian Once Daily
Major/CRNM Bleeding
Any Bleeding

FIG. 5



aPTT (Ratio to baseline)
Bleeding (%)
Twice daily
Once daily
Milvexian
Enoxaparin
25 mg
50 mg
100 mg
200 mg
25 mg
50 mg
200 mg
40 mg
Day 1, hour 2
Day 4, hour 4
Days 10-14
Any bleeding
Major or CRNM bleeding

FIG. 6



Milvexian
(mg/kg + mg/kg/h IV)
Vehicle
0.063 + 0.04
0.25 + 0.17
1 + 0.67
n = 6 per group
Carotid blood flow
(% control)
100
80
60
40
20
0
0
15
30
45
60
75
90
Time after injury (min)

FIG. 7



Rabbit ECAT
n = 6 per group
*P< 0.05 vs vehicle
Integrated blood flow
(% control)
100
80
60
40
20
0
*
*
*
32%
54%
76%
Vehicle
0.063+0.043
0.25+0.17
1+0.67
Milvexian (mg/kg + mg/kg/h IV)

FIG. 8




Rabbit
ECAT
Thrombus reduction (%)
100
80
60
40
20
0
1
10
100
1000
10000
Milvexian (nM)

FIG. 9




*$P$< 0.05 vs vehicle

FIG. 10



Rabbit
ECAT
Thrombus reduction (%)
aPTT (ratio)
0
20
40
60
80
100
0.5
1
1.5
2
2.5

FIG. 11




Treatment rabbit ECAT
Carotid blood flow (% control)
100
80
60
40
20
0
IV
0
15
30
45
60
75
90
Time (min)
Milvexian
(mg/kg + mg/kg/h IV)
Vehicle
0.25 + 0.17
1 + 0.67

FIG. 12




ASO=antisense oligonucleotide; C=concentration; FXI=Factor XI; FXI ASO=Factor XI antisense oligonucleotide; VTE=venous thromboembolism

FIG. 13